COMy 2023 | Safety & efficacy of cevostamab in patients with heavily pre-treated R/R multiple myeloma
Joshua Richter
• 12 May 2023
Joshua Richter, MD, Mount Sinai Medical Center, New York City, NY, provides updates on a Phase I clinical trial evaluating the use of cevostamab, an FcRH5-targeting bispecific antibody (BsAb), as fixed-duration monotherapy for patients with heavily pre-treated relapsed/refractory (R/R) multiple myeloma (NCT03275103). Dr Richter highlights the benefits of cevostamab over other bispecifics targeting BCMA and GPRC5D, and discusses positive outcomes from the study. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
